A MEDICINE COMPANY

ELI LILLY AND COMPANY

Q2 2024 EARNINGS CALL

08.08.24

Agenda

Introduction and Key Events
Dave Ricks, Chair and Chief Executive Officer

Q2 2024 Financial Results
Gordon Brooks, Interim Chief Financial Officer

R&D Update
Dan Skovronsky, M.D., Ph.D., Chief Scientific Officer

Closing Remarks
Dave Ricks, Chair and Chief Executive Officer

Question & Answer Session

Safe Harbor Provision

This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. The company's results may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; litigation and investigations; business development transactions; economic conditions; and changes in laws and regulations, including healthcare reform.

For additional information about the factors that affect the company's business, please see the company's latest Form 10-K and subsequent Forms 10-Q and 8-K filed with the Securities and Exchange Commission. Certain financial information in this presentation is presented on a non-GAAP basis. Investors should refer to the reconciliations included in this presentation and should consider the company's non-GAAP measures in addition to, not as a substitute for or superior to, measures prepared in accordance with GAAP. These materials are not intended to promote the products referenced herein or otherwise influence healthcare prescribing decisions. The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval or become commercially available for the uses being investigated.

The company undertakes no duty to update forward-looking statements except as required by applicable law.

Strategic Deliverables

PROGRESS SINCE THE LAST EARNINGS CALL

Invest in Current Portfolio

- **Gross Margin**: Non-GAAP gross margin of 82.0% in Q2
- **SG&A**: 10% increase primarily driven by investments in our launches and our people

Deliver Revenue Growth

- Revenue grew 36% in Q2 driven by Mounjaro®, Zepbound®, and Verzenio®; New Product[1] revenue grew nearly $3.5 billion
- Excluding the sale of rights to Baqsimi®, non-incretin revenue growth was 17% worldwide, with 25% revenue growth in the U.S.

Invest in Future Innovation

- **R&D**: 15% increase driven by continued investment in our portfolio and our people
- **Business Development**: Announced an agreement to acquire Morphic, a biopharmaceutical company developing oral integrin therapies
- **Capex:** Announced a new $5.3 billion commitment in the Lebanon, Indiana, manufacturing site bringing our total investment to $9 billion

Speed Life-Changing Medicines

- Kisunla™ approved in the U.S. for the treatment of adults with Alzheimer's disease
- Jaypirca® approved in Japan for the treatment of relapsed or refractory mantle cell lymphoma
- Submitted tirzepatide for the treatment of moderate-to-severe obstructive sleep apnea and obesity in the U.S. and EU
- Announced positive topline results from the SUMMIT Phase 3 trial of tirzepatide in heart failure with preserved ejection fraction and obesity

Return Capital to Shareholders: Distributed over $1 billion via **dividends** in Q2

[1] Refer to slide 10 for a list of New Products

Key Events Since Last Earnings Call

Regulatory

- **Kisunla** approved in the U.S. for Alzheimer's disease; received positive PMDA[1] opinion for **donanemab** in Japan
- **Jaypirca** approved in Japan for relapsed or refractory mantle cell lymphoma
- Submitted **tirzepatide** for moderate-to-severe obstructive sleep apnea in adults with obesity in the U.S. and EU
- Submitted **mirikizumab** for moderately to severely active Crohn's disease in Japan

Clinical

- Announced positive topline results from the SUMMIT Phase 3 trial of **tirzepatide** for the treatment of heart failure with preserved ejection fraction and obesity
- Announced positive topline results from the QWINT-2 and QWINT-4 Phase 3 trials of once-weekly **insulin efsitora alfa**
- Presented data from the SURMOUNT-OSA Phase 3 trials of **tirzepatide** at the American Diabetes Association Meeting showing up to 51.5% of participants met criteria for disease resolution[2]

Clinical (Cont)

- Presented data from the SYNERGY-NASH Phase 2 trial of **tirzepatide** at the European Association for the Study of the Liver showing more than half of patients achieved improvement in fibrosis at 52 weeks
- Presented data for **Verzenio**, **Retevmo®**, **olomorasib** and **imlunestrant** at the American Society of Clinical Oncology Annual Meeting
- Presented data from the VIVID-1 Phase 3 trial of **mirikizumab** at Digestive Disease Week

Other

- Announced a new $5.3 billion commitment in the Lebanon, Indiana, **manufacturing site** bringing our total investment to $9 billion
- Announced an agreement to acquire **Morphic**, a biopharmaceutical company developing oral integrin therapies
- Announced a collaboration with **OpenAI** to use their generative AI to invent novel microbials
- Announced the following **leadership changes:**
  - **Anat Ashkenazi**, chief financial officer, resigned effective July 31; **Gordon Brooks** appointed interim chief financial officer
  - **Melissa Seymour** joined as executive vice president of global quality effective July 22
  - **Alonzo Weems**, executive vice president of enterprise risk management and chief ethics and compliance officer, will retire effective end of 2024

[1] Pharmaceuticals and Medical Devices Agency
[2] In this context, disease resolution means achieving an apnea-hypopnea index (AHI) of fewer than 5 events per hour, or an AHI of 5-14 events per hour and an Epworth Sleepiness Scale score of ≤10

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information; Certain Line Items (Unaudited)

Dollars in millions; except per share data

	Q2 2024			
	GAAP Reported	Adjustments	Non-GAAP Adjusted	YoY Non-GAAP Adjusted Change
TOTAL REVENUE	$11,303	$ –	$11,303	36%
GROSS MARGIN	80.8%	1.2pp	82.0%	2.2pp
TOTAL OPERATING EXPENSE	$5,418	$(435)	$4,983	14%
OPERATING INCOME	$3,715	$574	$4,289	90%
OPERATING MARGIN	32.9%	5.0pp	37.9%	10.8pp
OTHER INCOME (EXPENSE)	$(198)	$148	$(50)	NM
EFFECTIVE TAX RATE	15.6%	0.9pp	16.5%	0.4pp
NET INCOME	$2,967	$574	$3,541	86%
EPS	$3.28	$0.64	$3.92	86%
Acquired IPR&D Charges per share*	$0.14	$ –	$0.14	56%

*Acquired IPR&D (in-process research and development) of $154 million (pre-tax)
Numbers may not add due to rounding; see slide 25 for a complete list of adjustments; NM = not meaningful

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information; Certain Line Items (Unaudited)

Dollars in millions; except per share data

	1H 2024			
	GAAP Reported	Adjustments	Non-GAAP Adjusted	YoY Non-GAAP Adjusted Change
TOTAL REVENUE	$20,071	$ –	$20,071	31%
GROSS MARGIN	80.8%	1.4pp	82.2%	3.0pp
TOTAL OPERATING EXPENSE	$10,003	$(435)	$9,568	16%
OPERATING INCOME	$6,224	$713	$6,937	79%
OPERATING MARGIN	31.0%	3.6pp	34.6%	9.2pp
OTHER INCOME (EXPENSE)	$(171)	$124	$(46)	NM
EFFECTIVE TAX RATE	13.9%	0.8pp	14.7%	–
NET INCOME	$5,210	$667	$5,876	74%
EPS	$5.76	$0.74	$6.50	74%
Acquired IPR&D Charges per share*	$0.24	$ –	$0.24	26%

*Acquired IPR&D of $265 million (pre-tax)
Numbers may not add due to rounding; see slide 26 for a complete list of adjustments; NM = not meaningful

Price/Rate/Volume Effect on Revenue

Dollars in millions

	Q2 2024					
	Amount	Price	FX Rate	Volume	Total	CER
U.S.	$7,835	15%	–	27%	42%	42%
EUROPE	1,404	2%	(1)%	18%	19%	20%
JAPAN	463	(6)%	(13)%	21%	2%	15%
CHINA	395	(2)%	(2)%	3%	(1)%	1%
REST OF WORLD	1,206	3%	(0)%	58%	61%	61%
TOTAL REVENUE	$11,303	10%	(1)%	27%	36%	37%

	1H 2024					
	Amount	Price	FX Rate	Volume	Total	CER
U.S.	$13,530	15%	–	21%	36%	36%
EUROPE	2,844	2%	1%	23%	25%	25%
JAPAN	827	(6)%	(11)%	15%	(2)%	9%
CHINA	771	(3)%	(2)%	5%	(0)%	2%
REST OF WORLD	2,099	1%	1%	46%	48%	47%
TOTAL REVENUE	$20,071	10%	(1)%	22%	31%	32%

Numbers may not add due to rounding

CER = price change + volume change

Q2 2024 Update on Select Products



New Products: Ebglyss®, Jaypirca, Mounjaro, Omvoh™, and Zepbound
Growth Products: Cyramza®, Emgality®, Jardiance®[1], Olumiant®, Retevmo, Taltz®, Trulicity®, Tyvyt®, and Verzenio

[1] Jardiance is part of the company's alliance with Boehringer Ingelheim. Lilly reports as revenue royalties received on net sales of Jardiance

NEW PRODUCTS

MOUNJARO
- U.S. T2D injectable incretins TRx SOM nearly 32% and NBRx SOM over 33% at end of Q2 2024

ZEPBOUND
- U.S. branded anti-obesity TRx and NBRx SOM approximately 36% at end of Q2 2024

JAYPIRCA
- Q2 2024 sales increased to $92 million, including a $19 million milestone related to Japan

OMVOH
- Launches in the U.S. and 14 international markets progressing well with increasing patient starts in Q2 2024

GROWTH PRODUCTS

JARDIANCE[1]
- U.S. TRx SOM over 64% at end of Q2 2024
- U.S. TRx grew over 24% vs. Q2 2023

TALTZ
- U.S. immunology TRx SOM nearly 6% at end of Q2 2024
- U.S. TRx grew over 6% vs. Q2 2023

TRULICITY
- U.S. T2D injectable incretins TRx SOM over 15% at end of Q2 2024

VERZENIO
- U.S. TRx grew nearly 24% vs. Q2 2023
- Growth driven by the early breast cancer indication

Zepbound U.S. Launch Progress



- Continue to see **exceptional growth trends** since launch that have **accelerated** as we ramp production
- All dosages of Zepbound **currently listed as available** on the FDA shortage website
- **Rapidly building** commercial formulary coverage in the U.S. – as of July 1 we had approximately 86% access
- Estimate **over 50%** of employers have opted-in to anti-obesity medications and expect modest growth as we work to expand coverage
- Plan to launch single-dose 2.5mg and 5mg **Zepbound vials** in the U.S. in the coming weeks

Source: IQVIA Monthly NPA data through June 2024

Capital Allocation

$ in Billions



* After tax

** Includes development milestones, closed acquisitions and cash outflows associated with equity investments

2024 Guidance

	Prior	Updated	Comments
REVENUE	$42.4 – $43.6 billion	$45.4 – $46.6 billion	Reflects greater confidence in incretin supply outlook and visibility into upcoming OUS launches, as well as strong momentum in non-incretin revenue growth
GROSS MARGIN – OPEX[1] REVENUE			
(GAAP)	32% – 34%	36% – 38%	Reflects increase in revenue guidance
(NON-GAAP)	33% – 35%	37% – 39%	
OTHER INCOME/(EXPENSE)			GAAP and non-GAAP changes reflect lower expected net interest expense; GAAP change also reflects net losses on investments in equity securities through Q2
(GAAP)	$(500) – $(400) million	$(525) – $(425) million	
(NON-GAAP)	$(500) – $(400) million	$(400) – $(300) million	
TAX RATE	Approx. 14%	Approx. 15%	Reflects changes in our forecasted mix of earnings in higher tax jurisdictions
EARNINGS PER SHARE[2]			GAAP and non-GAAP changes reflect update in revenue guidance and year-to-date acquired IPR&D charges of $0.24 per share; GAAP change also reflects net losses on investments in equity securities through Q2
(GAAP)	$13.05 – $13.55	$15.10 – $15.60	
(NON-GAAP)	$13.50 – $14.00	$16.10 – $16.60	

[1] OPEX is defined as the sum of research and development expenses and marketing, selling and administrative expenses
[2] 2024 assumes shares outstanding of approximately 904 million. Earnings per share (non-GAAP) reflects $0.49 adjustment for amortization of intangible assets
IPR&D = in-process research and development

FX assumptions of 1.07 (Euro), 160 (Yen) and 7.10 (Renminbi)

Tirzepatide SUMMIT Phase 3 Study

Phase 3 study of tirzepatide in adults with HFpEF and obesity



Reduced risk of worsening heart failure compared to placebo

—

38% reduction



Significantly reduced heart failure symptom severity and physical limitations

—

24.8-point* improvement



Reduced weight in people with and without type 2 diabetes

—

15.7%* reduction

Overall safety profile consistent with previously reported tirzepatide studies
Plan to submit study results to the FDA and other regulatory agencies starting later this year

HFpEF = heart failure with preserved ejection fraction
*Note: Results for efficacy estimand which represents efficacy prior to discontinuation of study drug

Lilly Select NME and NILEX Pipeline

August 6, 2024



Potential Key Events 2024

New since last update

Phase 3 Initiations

- Retatrutide for type 2 diabetes
- Retatrutide for cardiovascular outcomes in chronic weight management
- Lepodisiran [Lp(a) SiRNA] for cardiovascular disease
- Olomorasib [KRAS G12C] for first-line non-small cell lung cancer
- Remternetug for early Alzheimer's disease [efficacy trials]
- Lebrikizumab for chronic rhinosinusitis with nasal polyposis
- Lebrikizumab for allergic rhinitis due to perennial allergens

Phase 3 Data Disclosures

- Tirzepatide for obstructive sleep apnea [SURMOUNT-OSA]
- Tirzepatide for HFpEF [SUMMIT]
- Tirzepatide H2H study vs. semaglutide [SURMOUNT-5][1]
- Insulin efsitora alfa for diabetes [QWINT-1 / 2 / 3 / 4 / 5]
- Abemaciclib for metastatic CRPC[2] [CYCLONE-2]
- Imlunestrant for metastatic breast cancer [EMBER-3]

Regulatory Submissions

- Mirikizumab for Crohn's disease [US / EU / J]
- Tirzepatide for obstructive sleep apnea [US/EU]
- Tirzepatide for HFpEF [US]
- Tirzepatide for chronic weight management [JP]
- Imlunestrant for metastatic breast cancer [US/EU/J]
- Pirtobrutinib for CLL prior BTKi + BCL2 [EU/J]

Regulatory Actions

- Lebrikizumab for atopic dermatitis [US/J]
- Donanemab for early Alzheimer's disease[3] [US/EU/J]
- Empagliflozin[4] for chronic kidney disease [J]
- Pirtobrutinib for MCL prior BTKi [J]
- Tirzepatide for obstructive sleep apnea [US]

[1] Classified as a Phase 3B/4 study
[2] CRPC = castrate-resistant prostate cancer
[3] Under the traditional approval pathway
[4] Jardiance is part of the company's alliance with Boehringer Ingelheim. Lilly reports as revenue royalties received on net sales of Jardiance

Tirzepatide SURMOUNT-OSA Phase 3 Studies

Percentage of participants reaching criteria for disease resolution
AHI < 5 or with AHI 5-14 and ESS ≤ 10



- Phase 3 studies evaluated tirzepatide in participants with moderate-to-severe OSA and obesity
- In a key secondary endpoint, up to 51.5% of participants on tirzepatide reached criteria for disease resolution
- Submitted tirzepatide for the treatment of moderate-to-severe OSA and obesity to the FDA and the EMA; expect U.S. regulatory action as early as the end of 2024

AHI = apnea-hypopnea index, expressed as events per hour; ESS = Epworth Sleepiness Scale, a standard questionnaire designed to assess excessive daytime sleepiness; OSA = obstructive sleep apnea
Note: Results for efficacy estimand which represents efficacy prior to discontinuation of study drug
Tirzepatide v. placebo: *p<0.001

Tirzepatide SYNERGY-NASH Phase 2 Study

Percentage of participants with a decrease of ≥1 fibrosis stage and no worsening of MASH at week 52



- Phase 2 study in adults with biopsy-proven MASH with stage 2 or 3 fibrosis
- In a secondary endpoint, more than half of patients taking tirzepatide achieved improvement in fibrosis at 52 weeks
- Engaged with regulatory authorities on a potential Phase 3 registration strategy

MASH = metabolic dysfunction-associated steatohepatitis; TZP = tirzepatide
Note: Results for the treatment-regimen estimand which represents the efficacy for randomized participants regardless of treatment discontinuation.

Q2 2024 Summary

- Revenue grew 36% driven by Mounjaro, Zepbound, and Verzenio
- Continued to speed life-changing medicines to patients:
  - Kisunla approved in the U.S. for the treatment of adults with Alzheimer's disease
  - Submitted tirzepatide for the treatment of moderate-to-severe obstructive sleep apnea and obesity in the U.S. and EU
  - Announced positive topline results from the SUMMIT Phase 3 trial of tirzepatide in heart failure with preserved ejection fraction and obesity
- Q2 investment growth largely driven by recent and upcoming launches, acceleration in pipeline development, and progress on an ambitious manufacturing expansion agenda
- Returned over $1 billion to shareholders via the dividend



Supplemental Slides

2024 Income Statement – Reported

Dollars in millions; except per share data

	Q2 2024	Change	1H 2024	Change
TOTAL REVENUE	$11,303	36%	$20,071	31%
GROSS MARGIN	80.8%	2.5pp	80.8%	3.3pp
TOTAL OPERATING EXPENSE*	$5,418	24%	$10,003	22%
OPERATING INCOME	$3,715	75%	$6,224	72%
OPERATING MARGIN	32.9%	7.3pp	31.0%	7.3pp
OTHER INCOME (EXPENSE)	$(198)	NM	$(171)	NM
EFFECTIVE TAX RATE	15.6%	–	13.9%	(0.2)pp
NET INCOME	$2,967	68%	$5,210	68%
EARNINGS PER SHARE	$3.28	68%	$5.76	67%

* Includes research and development expense; marketing, selling and administrative expense; acquired in-process research and development charges; and asset impairment, restructuring and other special charges (as applicable)
NM = not meaningful

(Gross Margin – OPEX[1]) / Revenue Ratio



Non-GAAP Ratio (Gross Margin – OPEX[1]) / Revenue:	24.8%	28.3%	37.4%	34.3%	31.5%	39.3%
GAAP Ratio (Gross Margin – OPEX[1]) / Revenue:	23.0%	26.7%	36.1%	32.9%	29.9%	38.1%

[1] OPEX is defined as the sum of research and development expenses and marketing, selling and administrative expenses
The line in the graph is the non-GAAP moving annual total (i.e. trailing 4 quarters) while the rows of numbers are from specific quarters
Note: The Non-GAAP ratios for the periods presented exclude the amortization of intangible assets. The applicable impact of amortization of intangible assets can be found in the reconciliation tables of the respective quarterly earnings releases.

Effect of FX on 2024 Results

Year-on-Year Change

REPORTED	Q2 2024		1H 2024	
	With FX	w/o FX	With FX	w/o FX
TOTAL REVENUE	36%	37%	31%	32%
COST OF SALES	20%	20%	12%	12%
GROSS MARGIN	40%	42%	37%	38%
OPERATING EXPENSE	24%	24%	22%	22%
OPERATING INCOME	75%	78%	72%	74%
EARNINGS PER SHARE	68%	71%	67%	70%

NON-GAAP	With FX	w/o FX	With FX	w/o FX
TOTAL REVENUE	36%	37%	31%	32%
COST OF SALES	21%	21%	12%	12%
GROSS MARGIN	40%	41%	37%	37%
OPERATING EXPENSE	14%	14%	16%	17%
OPERATING INCOME	90%	93%	79%	81%
EARNINGS PER SHARE	85%	89%	74%	76%

Presentation includes GAAP and non-GAAP figures excluding impact of foreign exchange rates. Current period figures recalculated by keeping constant the exchange rates from the base period.

EPS Reconciliation

	Q2 2024	Q2 2023	% Change	1H 2024	1H 2023	% Change
EARNINGS PER SHARE (REPORTED)	$3.28	$1.95	68%	$5.76	$3.44	67%
ASSET IMPAIRMENT, RESTRUCTURING AND OTHER SPECIAL CHARGES	0.38	–	NM	0.38	–	NM
NET LOSSES (GAINS) ON INVESTMENTS IN EQUITY SECURITIES	0.14	0.05	NM	0.12	0.07	71%
AMORTIZATION OF INTANGIBLE ASSETS	0.12	0.11	9%	0.24	0.22	9%
EARNINGS PER SHARE (NON-GAAP)	$3.92	$2.11	86%	$6.50	$3.73	74%
Acquired IPR&D	$0.14	$0.09	56%	$0.24	$0.19	26%

Numbers may not add due to rounding; see slides 25 & 26 for more details on these adjustments; NM = not meaningful

Q2 2024 Income Statement Notes

Q2 2024 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE:

- asset impairment, restructuring and other special charges totaling $435 million (pre-tax), or $0.38 per share (after-tax); and
- net losses on investments in equity securities totaling $147.7 million (pre-tax), or $0.14 per share (after-tax); and
- amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling $139.1 million (pre-tax), or $0.12 per share (after-tax).

Q2 2023 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE:

- amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling $126.4 million (pre-tax), or $0.11 per share (after-tax); and
- net losses on investments in equity securities totaling $53.9 million (pre-tax), or $0.05 per share (after-tax).

1H 2024 Income Statement Notes

1H 2024 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE:

- asset impairment, restructuring and other special charges totaling $435 million (pre-tax), or $0.38 per share (after-tax); and
- amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling $278.2 million (pre-tax), or $0.24 per share (after-tax); and
- net losses on investments in equity securities totaling $124.3 million (pre-tax), or $0.12 per share (after-tax).

1H 2023 NON-GAAP INFORMATION HAS BEEN ADJUSTED TO EXCLUDE:

- amortization of intangibles (cost of sales) primarily associated with costs of marketed products acquired or licensed from third parties totaling $252.2 million (pre-tax), or $0.22 per share (after-tax); and
- net losses on investments in equity securities totaling $76.5 million (pre-tax), or $0.07 per share (after-tax).

Comparative EPS Summary 2023/2024

Dollars

	1Q23	2Q23	3Q23	4Q23	2023	1Q24	2Q24	3Q24	4Q24	2024
Reported	1.49	1.95	(0.06)	2.42	5.80	2.48	3.28			
Non-GAAP	1.62	2.11	0.10	2.49	6.32	2.58	3.92			

Numbers may not add due to rounding
For a complete reconciliation to reported earnings, see slide 24 and our earnings press release dated August 8, 2024

Q2 2024 Mounjaro Sales Increased $2.1B

$ in Millions

U.S. sales were $2.4 billion
International sales were $677 million



U.S. TRx SOM and Market Volume



Note: Lilly T2D Injectable Incretins consist of Mounjaro & Trulicity 13 Wk RA TRx SOM

Source: IQVIA NPA TRx 3MMA, weekly data June 28, 2024; RA = rolling average
TRx data is representative of the injectable incretin market

Q2 2024 Verzenio Sales Increased 44%

$ in Millions

U.S. sales increased 46%
International sales increased 39%



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data June 28, 2024; RA = rolling average

Q2 2024 Trulicity Sales Decreased 31%

$ in Millions

U.S. sales decreased 36%
International sales decreased 16%



U.S. TRx SOM and Market Volume



Note: Lilly T2D Injectable Incretins consist of Mounjaro & Trulicity 13 Wk RA TRx SOM

Source: IQVIA NPA TRx 3MMA, weekly data June 28, 2024; RA = rolling average
TRx data is representative of the injectable incretin market

Q2 2024 Taltz Sales Increased 17%

$ in Millions

U.S. sales increased 14%
International sales increased 23%



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data June 28, 2024; RA = rolling average
TRx data is representative of the full molecule market

Q2 2024 Jardiance Sales Increased 15%

$ in Millions

U.S. sales increased 11%
International sales increased 21%



U.S. TRx SOM and Market Volume



Source: IQVIA NPA TRx 3MMA, weekly data June 28, 2024; RA = rolling average

[1] Jardiance includes Glyxambi and Synjardy. Jardiance is part of the company's alliance with Boehringer Ingelheim. Lilly reports as revenue royalties received on net sales of Jardiance.

Q2 2024 Humalog Sales Increased 43%

$ in Millions

U.S. sales increased 89%
International sales decreased 7%



U.S. TRx SOM



Source: IQVIA NPA TRx 3MMA, weekly data June 28, 2024; RA = rolling average

Select Trials – Donanemab

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04437511	Alzheimer Disease	A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)	3	1736	Change from Baseline on the integrated Alzheimer's Disease Rating Scale (iADRS)	Apr 2023	Aug 2025
NCT05738486	Alzheimer Disease	A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)	3	800	Percentage of Participants with Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E)	May 2024	May 2025
NCT05508789	Alzheimer Disease	A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)	3	1500	Change from Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS)	Apr 2027	Apr 2027
NCT05026866	Alzheimer Disease	A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)	3	2600	Time to clinical progression as measured by Clinical Dementia Rating - Global Score (CDR-GS)	Nov 2027	Nov 2027

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 24, 2024

Select Trials – Imlunestrant

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04975308	Breast Neoplasms	A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3)	3	866	Progression Free Survival (PFS) in the Intent-to-Treat (IIT) Population	Jun 2024	Aug 2027
NCT05514054	Breast Neoplasms	A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)	3	6000	Invasive Disease-Free Survival (IDFS)	Oct 2027	Mar 2032

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 22, 2024

Select Trials – Lebrikizumab

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05369403	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab (ADapt)	3	120	Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) >75% Reduction in EASI Score	Jan 2024	Dec 2024
NCT05372419	Atopic Dermatitis	A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color (ADmirable)	3	80	Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) (≥75% reduction from baseline in EASI)	May 2024	Dec 2024
NCT04392154	Atopic Dermatitis	Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)	3	1188	Percentage of Participants Discontinued from Study Treatment due to Adverse Events through the Last Treatment Visit	Jun 2024	Apr 2025
NCT05559359	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-1)	3	300	Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) ≥75% Reduction from Baseline in EASI Score	May 2025	Sep 2025
NCT06280716	Atopic Dermatitis	A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis (ADvance-Asia)	3	430	Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) ≥75% Reduction from Baseline in EASI Score	Dec 2025	Nov 2026
NCT05735483	Atopic Dermatitis	A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2)	3	250	Percentage of Participants Discontinued From Study Treatment due to Adverse Events (AEs)	Jun 2026	Jun 2026

* Molecule may have multiple indications

** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 23, 2024

Select Trials – Lepodisiran

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05565742	Lipoprotein Disorder	A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)] (ALPACA)	2	216	Percent Change from Baseline in Time Averaged Lipoprotein(a) [Lp(a)]	Oct 2023	Oct 2024
NCT06292013	Atherosclerotic Cardiovascular Disease (ASCVD)[1]	A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	3	12500	Time to First Occurrence of Any Component of the Major Adverse Cardiac Event (MACE)-4 Composite Endpoint	Mar 2029	Mar 2029

[1] Reduction of major adverse cardiovascular events (MACE) in patients with Atherosclerotic Cardiovascular Disease (ASCVD)

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 22, 2024

Select Trials – Mirikizumab

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04232553	Crohn's Disease	A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)	3	778	Percentage of Participants Achieving Endoscopic Response	Nov 2024	Dec 2026
NCT03524092	Ulcerative Colitis	A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT-2)	3	1177	Percentage of Participants in Clinical Remission at Week 40	Nov 2021	Dec 2024
NCT03519945	Ulcerative Colitis	A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT-3)	3	1063	Percentage of Participants in Clinical Remission	Jul 2026	Dec 2027

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 23, 2024

Select Trials – Orforglipron

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05971940	Type 2 Diabetes	A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise (ACHIEVE-1)	3	520	Change from Baseline in Hemoglobin A1c (HbA1c)	Apr 2025	Apr 2025
NCT05803421	Type 2 Diabetes	A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)	3	2620	Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death]	Apr 2025	Dec 2025
NCT06109311	Type 2 Diabetes	A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)	3	520	Change from Baseline in Hemoglobin A1c (HbA1c) Compared to Placebo	Jun 2025	Jun 2025
NCT06010004	Type 2 Diabetes	A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes (ACHIEVE-J)	3	399	Number of Participants with Treatment Emergent Adverse Events (TEAEs)	Jun 2025	Jun 2025
NCT06045221	Type 2 Diabetes	A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin (ACHIEVE-3)	3	1576	Change from Baseline in Hemoglobin A1c (HbA1c)	Jul 2025	Jul 2025

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 22, 2024

Select Trials – Orforglipron (Cont.)

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT06192108	Type 2 Diabetes	A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)	3	888	Change from Baseline in Hemoglobin A1c (HbA1c)	Oct 2025	Oct 2025
NCT05872620	Obesity	A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)	3	1500	Mean Percent Change from Baseline in Body Weight	Jun 2025	Jun 2025
NCT05931380	Obesity	A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease (ATTAIN-J)	3	236	Mean Percent Change in Body Weight	Jun 2025	Jul 2025
NCT05869903	Obesity	A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)	3	3000	Mean Percent Change from Baseline in Body Weight	Sep 2025	Sep 2027

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 22, 2024

Select Trials – Pirtobrutinib

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04666038	Chronic Lymphocytic Leukemia	Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-321)	3	250	To evaluate progression-free survival (PFS) of LOXO-305 monotherapy (Arm A) compared to investigator's choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) (Arm B)	Aug 2023	May 2027
NCT05023980	Chronic Lymphocytic Leukemia	A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)	3	250	To evaluate progression-free survival (PFS) of pirtobrutinib (Arm A) compared to bendamustine and rituximab (Arm B)	Jan 2025	May 2026
NCT04965493	Chronic Lymphocytic Leukemia	A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (BRUIN CLL-322)	3	600	To evaluate progression-free survival (PFS) of pirtobrutinib plus venetoclax and rituximab (Arm A) compared to venetoclax and rituximab (Arm B)	Apr 2026	Jan 2027
NCT05254743	Chronic Lymphocytic Leukemia	A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-314)	3	650	Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR): Overall Response Rate (ORR)	Feb 2025	Aug 2028
NCT04662255	Lymphoma, Mantle-Cell	Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (BRUIN MCL-321)	3	500	To compare progression-free survival (PFS) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL)	Dec 2025	Jul 2026

* Molecule may have multiple indications

** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 25, 2024

Select Trials – Remternetug

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05463731	Alzheimer Disease	A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)	3	600	Percentage of Participants Who Reach Amyloid Plaque Clearance on Amyloid PET Scan for Remternetug versus Placebo	Oct 2025	Oct 2026

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, June 21, 2024

Select Trials – Retatrutide

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05882045	Obesity	A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)	3	1800	Percent Change from Baseline in Body Weight	Jan 2026	Feb 2026
NCT05931367	Obesity	A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (TRIUMPH-4)	3	405	Percent Change from Baseline in Body Weight and Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score	Feb 2026	Mar 2026
NCT05929066	Obesity	A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1)	3	2100	Percent Change From Baseline in Body Weight	Apr 2026	May 2026
NCT05929079	Obesity	A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2)	3	1000	Percent Change from Baseline in Body Weight	May 2026	May 2026
NCT06383390	Obesity	The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)	3	10000	Time to First Occurrence of Composite Endpoints, A composite endpoint includes nonfatal myocardial infarction (MI), nonfatal stroke, cardiovascular (CV) death, or hospitalization or urgent visit due to heart failure (HF) Time to First Occurrence of Composite Endpoint of End Stage Kidney Disease (ESKD), ≥ 40% Sustained Decline in Estimated Glomerular Filtration Rate (eGFR), CV Death or Renal Death	Feb 2029	Feb 2029

* Molecule may have multiple indications

** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 24, 2024

Select Trials – Retatrutide (Cont.)

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05936151	Chronic Kidney Disease	A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes	2	120	Change from Baseline in Glomerular Filtration Rate (GFR)	Nov 2025	Nov 2025
NCT06354660	Type 2 Diabetes	Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)	3	480	Change from Baseline in Hemoglobin A1c (HbA1c)	Jun 2026	Jul 2026
NCT06297603	Type 2 Diabetes	Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)	3	320	Change from Baseline in Hemoglobin A1c (HbA1c)	Sep 2026	Oct 2026
NCT06260722	Type 2 Diabetes	Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)	3	1250	Change from Baseline in Hemoglobin A1c (HbA1c)	Dec 2026	Mar 2027

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 24, 2024

Select Trials – Retevmo

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT04211337	Medullary Thyroid Cancer	A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)	3	291	Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)	May 2023	Feb 2026
NCT04194944	Non-Small Cell Lung Cancer	A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)	3	261	Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) (with Pembrolizumab)	May 2023	Jun 2026
NCT03157128	Non-Small Cell Lung Cancer	A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)	1|2	875	Phase 1: MTD; Phase 2: ORR	Feb 2025	Feb 2026
NCT04819100	Carcinoma, Non-Small-Cell Lung	A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)	3	170	Event-Free Survival (EFS)	May 2027	Aug 2032

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, June 20, 2024

Select Trials – Tirzepatide

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05822830	Obesity	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities (SURMOUNT-5)	3	700	Percent Change from Baseline in Body Weight	Nov 2024	Nov 2024
NCT06047548	Obesity	A Study of Tirzepatide (LY3298176) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-MAINTAIN)	3	400	Percent Maintenance of Body Weight (BW) Reduction Achieved during the 60-Week Weight Loss Period	May 2026	May 2026
NCT06075667	Obesity	A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS)	3	150	Percent Change from Baseline in Body Mass Index (BMI)	Oct 2026	Oct 2026
NCT06439277	Obesity	A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)	3	300	Percent Change from Baseline in Body Mass Index (BMI)	May 2027	Jun 2027
NCT05556512	Obesity	A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)	3	15374	Time to First Occurrence of Any Component Event of Composite (All-Cause Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Coronary Revascularization, or Heart Failure Events)	Oct 2027	Oct 2027

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 25, 2024

Select Trials – Tirzepatide (Cont.)

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT05260021	Type 2 Diabetes	A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both (SURPASS-PEDS)	3	99	Change From Baseline in Hemoglobin A1c (HbA1c)	Aug 2024	Feb 2025
NCT04255433	Type 2 Diabetes	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT)	3	13299	Time to First Occurrence of Death from Cardiovascular (CV) Causes, Myocardial Infarction (MI), or Stroke (MACE-3)	Jun 2025	Jun 2025
NCT06037252	Type 2 Diabetes	A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity	2	350	Percent Change From Baseline in Body Weight	Jan 2026	Oct 2026
NCT05536804	CKD	A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TREASURE-CKD)	2	140	Change from Baseline in Kidney Oxygenation in Participants With or Without T2D [Time Frame: Baseline, Week 52]; Blood oxygenation-level dependent magnetic resonance imaging (BOLD MRI)	Jan 2026	Feb 2026

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 25, 2024

Select Trials – Verzenio

Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
NCT03155997[1]	Breast Cancer	Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)	3	5637	Invasive Disease-Free Survival (IDFS)	Mar 2020	May 2029
NCT05169567	Breast Neoplasm	Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMonarch)	3	368	Progression-Free Survival (PFS)	Feb 2024	Feb 2026

[1] Also lists NSABP Foundation Inc

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 22, 2024

Select Trials – Early Phase Cardiometabolic Health

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Bimagrumab	NCT05616013	Obesity	Safety and Efficacy of Bimagrumab and Semaglutide in Adults who are Overweight or Obese	2	507	Change from baseline in body weight at 48 weeks	May 2024	Jun 2025
Mazdutide	NCT06124807	Obesity	A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight	2	165	Percent Change from Baseline in Body Weight	Nov 2024	May 2025
Eloralintide	NCT06230523	Obesity	A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight	2	250	Percent Change from Baseline in Body Weight	Jun 2025	Sep 2025
Volenrelaxin	NCT05592275	Heart Failure	A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)	2	456	Change from Baseline in Left Atrial Reservoir Strain (LARS)	Nov 2025	Jan 2026

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 22, 2024

Select Trials – Early Phase Cardiometabolic Health (Cont.)

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
DACRA QW II	NCT05380323	Obesity	A Study of LY3541105 in Healthy and Overweight Participants	1	205	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Aug 2024	Aug 2024
LA-ANP	NCT06148272	Healthy	A Study of LY3971297 in Healthy Participants and Participants With Obesity and Hypertension	1	188	Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Feb 2025	Feb 2025
GS Insulin Receptor Agonist	NCT06280703	Healthy	A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)	1	70	Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration	Feb 2025	Feb 2025
SCAP siRNA	NCT06007651	Dyslipidemias	A Study of LY3885125 in Participants With Dyslipidemia or Non-Alcoholic Fatty Liver Disease (NAFLD)	1	112	Part A: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Apr 2025	Apr 2025
PNPLA3 siRNA	NCT05395481	Non-Alcoholic Fatty Liver Disease	A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Nonalcoholic Fatty Liver Disease	1	176	Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Dec 2025	Dec 2025

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 22, 2024

Select Trials – Early Phase Immunology

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Peresolimab	NCT05516758	Rheumatoid Arthritis	A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (RESOLUTION-1)	2	491	Percentage of Participants Achieving American College of Rheumatology (ACR)20	Nov 2023	Jan 2025
Ucenprubart	NCT05911841	Atopic Dermatitis	A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis	2	260	Percentage of Participants Achieving Eczema Area and Severity Index (EASI) 75	Jun 2025	Mar 2026
KV1.3 Antagonist	NCT06176768	Plaque Psoriasis	A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis	2	75	Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI 75)	Apr 2025	Jul 2025
Eltrekibart	NCT06046729	Hidradenitis Suppurativa	A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa	2	350	Percentage of Participant Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)	Aug 2025	Jul 2026
Ocadusertib[1]	NCT05848258	Rheumatoid Arthritis	An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis	2	380	Phase 2a: Change from Baseline in Disease Activity Score - high-sensitivity C-reactive protein (DAS28-hsCRP)	Feb 2026	Jul 2026

[1] Also lists Rigel Pharmaceuticals

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 24, 2024

Select Trials – Early Phase Immunology (Cont.)

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
CD19 Antibody	NCT06220669	Multiple Sclerosis	A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis	2	200	Cumulative Number of New T1 Gadolinium-Enhancing (GdE) Lesions	Aug 2027	Aug 2028
Itaconate Mimetic	NCT06153355	Healthy	A First-In-Human Study of LY3839840 in Healthy Participants	1	112	Number of participants with one or more Adverse Event (s) (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration	Aug 2024	Aug 2024
DC-853	NCT06311656	Healthy	A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants	1	77	Number of participants with one or more Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs)	Nov 2024	Nov 2024

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 24, 2024

Select Trials – Early Phase Neurodegeneration

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
O-GlcNAcase Inh.	NCT05063539	Alzheimer Disease	A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease	2	330	Change from Baseline to End Time Point in Integrated Alzheimer's Disease Rating Scale (iADRS)	Jul 2024	Aug 2024
Mevidalen	NCT06538116	Alzheimer Disease	A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease	2	300	Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS)	Dec 2025	Jan 2026
SARM1 CNS Inhibitor	NCT05492201	Healthy	A Study of LY3873862 in Healthy Participants	1	100	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Jun 2025	Jun 2025

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, August 5, 2024

Select Trials – Early Phase Neurodegeneration (Cont.)

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
OTOF Gene Therapy	NCT05821959	Sensorineural Hearing Loss, Bilateral	Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss	1|2	14	Frequency of Adverse Events (AEs)	Oct 2028	Oct 2028
GRN Gene Therapy	NCT04408625	Frontotemporal Dementia	Phase 1/2 Clinical Trial of PR006 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN) (PROCLAIM)	1|2	30	Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events Leading to discontinuation	Aug 2029	Aug 2029
GBA1 Gene Therapy	NCT04127578	Parkinson Disease	Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)	1|2	20	Cumulative number of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Jun 2029	Jun 2029
GBA1 Gene Therapy	NCT05487599	Gaucher Disease	A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)	1|2	15	Incidence and severity of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	Oct 2030	Oct 2030

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 24, 2024

Select Trials – Early Phase Oncology

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Olomorasib	NCT06119581	Carcinoma, Non-Small-Cell Lung	A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)	3	1016	PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded independent central review (BICR)	Oct 2026	Oct 2029
Olomorasib[1]	NCT04956640	Carcinoma, Non-Small-Cell Lung	Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)	1|2	550	Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY3537982 monotherapy	Jun 2026	Jun 2026
FGFR3 Selective	NCT05614739	Urinary Bladder Neoplasms	A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3	1	180	Phase 1a: To determine the recommended phase 2 dose (RP2D)/optimal dose of LOXO-435: Safety, number of participants with dose-limiting toxicities (DLTs)	Jun 2025	Jun 2025
Nectin-4 ADC 1	NCT06238479	Metastatic Solid Tumor	A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors	1	280	Phase 1a: To determine the recommended dose of LY4101174: Number of participants with dose-limiting toxicities (DLTs)	Aug 2026	Mar 2027

[1] Also lists Merck Sharp & Dohme LLC

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 29, 2024

Select Trials – Early Phase Oncology (Cont.)

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
FOLR1 ADC	NCT06400472	Ovarian Neoplasms	A Study of LY4170156 in Participants With Selected Advanced Solid Tumors	1	220	Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY4170156, Number of participants with dose-limiting toxicities (DLTs)	Feb 2027	Apr 2027
NECTIN-4 ADC 2	NCT06465069	Metastatic Solid Tumor	A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors	1	220	Phase 1a: To determine the recommended phase 2 dose (RP2D) or optimal dose of LY4052031	May 2027	May 2027
225Ac-PSMA-62 PNT2001	NCT06229366	Prostate Cancer	[Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer	1	48	Recommended Phase II Dose (RP2D), Treatment emergent adverse events (TEAEs) and dose limiting toxicities (DLTs) for \[Ac-225\]-PSMA-62	Aug 2027	Mar 2032

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 29, 2024

Select Trials – Early Phase Pain

Molecule	Study	Indication*	Title	Phase	Patients	Primary Outcome**	Primary Completion	Completion
Mazisotine (SSTR4 Agonist)	NCT06074562	Diabetic Peripheral Neuropathy	A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain	2	410	Mean Change from Baseline for Average Pain Intensity Numeric Rating Scale (API-NRS)	Jan 2025	Jan 2025

* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes

Source: clinicaltrials.gov, July 19, 2024

A MEDICINE COMPANY